logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Why Moderna Stock Is Rallying

In the NEWS: Coronavirus Yesterday the CDC announced the first US case of coronavirus which has killed 17 and sickened hundreds of people in China. According to officials the first US case is of a very healthy 30 year old...

Read More

January 22, 2020

0

Has the Time Come for Curis Inc to Flex Its Muscles?

Curis Inc IND Application Cleared by the US FDA Curis Inc ( CRIS ) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CI-8993, the first-in-class monoclonal anti-VISTA antibody. Continue reading...

Read More

June 10, 2020

0

The European Medicine Agency Validates the Gilead Application for a CAR T Product for Mantle Cell Lymphoma

The EMA validated the MAA for the Gilead Investigational CAR T Product for MCL Kite , a  Gilead ( GILD ) company, announced that the European Medicines Agency ( EMA ) has validated the Marketing Authorization Application ( MAA )...

Read More

January 29, 2020

0

Reata Pharmaceuticals Stock Soared

Reata Pharmaceuticals Stock is Flying High Here is another example of why analysts can no longer use the same old measures to evaluate the biotechnology firms. They cannot continue to ignore the values of the firms’ technologies and very promising...

Read More

June 11, 2020

0

Agenus fincances through Tokenization. Amgen's critics hit hard. Why BioTime could thrive on OncoCyte news

AGENUS Agenus (AGEN)  announced the upcoming launch of its Biotech Electronic Security Token (BEST);  the first digital security offering in healthcare. Tokenization enables qualified investors to directly invest in a single biotech product while preserving shareholder equity. Garo Armen, Chairman...

Read More

January 30, 2019

0

Regenxbio, Moderna Therapeutics and Other Biotech Stocks Posted Gains in a Bad Market Day

Regenxbio, Moderna and Others Regenxbio ( RGNX ) announced several poster presentations including interim data from its Phase I/II trial of RGX-121 for the treatment of Mucopolysaccharidosis Type II ( MPS II ), and family surveys focused on patients with...

Read More

January 30, 2020

0

Merck's superior accomplishments

Merck (MRK)   announced its Q4 2018 financial results . The firm outperformed itself and delighted us with regard to picking its stock on time. Merck compensated those who bet on it the day it was added to the Prohost...

Read More

February 1, 2019

0

Halozyme signs another license agreement this time with argenx

Halozyme Therapeutics (HALO)   and  argenx (ARGX)  announced a global collaboration and license agreement offering argenx the right to use Halozyme's ENHANZE® drug delivery technology to develop multiple subcutaneous product formulations for current or future argenx product candidates. The agreement...

Read More

February 5, 2019

0

The Time Has Come for Agenus to Excel. See Also: Why Evoke Pharma Traded UP Today

Agenus Has Two Separate Press Releases In the First Press Release from Agenus: Agenus ( AGEN ) announced that it will be making a scientific presentation today on optimal anti-cancer combinations with Fc enhanced anti-CTLA-4, AGEN1181 at the American Association...

Read More

June 22, 2020

0

ImmunoGen's Report and Standing. Why Biogen Is Experiencing a Selloff

ImmunoGen & Biogen News About ImmunoGen ImmunoGen (IMGN)   is a creator and developer of antibody-drug conjugates (ADCs) aimed at improving cancer treatments. ImmunoGen aims to disrupt the progression of cancer through its conjugated targeted monoclonal antibodies. ImmunoGen’s lead ADC...

Read More

February 8, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 90
  • 91
  • 92
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy